A Clinical Lab Partner You Can Trust

Innovations in Testing

Revolutionizing Diagnostics

Explore Our Latest Assay Innovations

All of our assays are designed to enhance diagnostic accuracy and improve patient outcomes. Our latest innovations include ExPeCT™ anti-CD19 CAR T, a breakthrough in assessing CAR T cell therapy efficacy, and NeXGen™ Fungal / AFB NGS, which offers advanced next-generation sequencing for comprehensive genomic analysis. Additionally, we are proud to introduce tests for TTV and NTM, addressing important viral and mycobacterial infections, along with TA-TMA for stem cell transplant patients. Explore our website to learn more about these pioneering tests and how they can support your clinical needs.

Introduction to Our Newest Assays

Key Highlights and Summaries

ExPeCT™ anti-CD19 (FMC63) CAR T assay is a specialized test designed to monitor patients undergoing CAR T-cell therapy. This comprehensive assay evaluates the persistence and function of CAR T cells, providing critical insights into the therapy's effectiveness. By delivering timely and accurate results, CAR T ExPeCT supports personalized treatment decisions and enhances patient management throughout their therapy journey.

NeXGen™ Fungal / AFB NGS assay product from Eurofins Viracor offers advanced next-generation sequencing to detect fungal pathogens and acid fast bacteria effectively. This high-throughput testing utilizes a non-invasive sample type and provides rapid and accurate identification of a wide range of microorganisms, aiding in timely clinical decision-making. With its comprehensive analysis, NeXGen NGS enhances the understanding of complex infections, ultimately improving patient outcomes through targeted therapies.

The TTViWATCH (Torque Teno Virus) viral load monitoring assay utilizes quantitative PCR to detect Torque Teno Virus (TTV) in patient samples, providing valuable insights into immune status and viral load. This sensitive and specific assay helps clinicians monitor immunocompromised patients, particularly those undergoing transplant or cancer therapies. By offering timely results, the TTV test aids in the assessment of complications and has the potential to guide personalized treatment strategies.

The NTM Nontuberculous mycobacterial assay allows for rapid and accurate identification and differentiation of MAC, MAbC and Mycobacterium spp. by RT-PCR, direct from clinical samples facilitating timely diagnosis and treatment of infections. By supporting personalized care, the NTM test aids healthcare providers in managing complex cases associated with these pathogens, particularly in immunocompromised patients.

The TA-TMA (transplant associated thrombotic microangiopathy) assays stand out for their comprehensiveness, offering clinicians a complete assessment of complement pathway regulation and potential deregulation with validated assays for Eculizumab, CH50, and sC5b-9. Our comprehensive approach ensures that clinicians receive detailed results across all three critical areas, empowering them to make informed decisions about patient treatment promptly, thanks to our industry-leading 24 hour turnaround times. These tests help monitor complement activity and potential complications associated with complement-mediated diseases. By offering rapid and precise results, the TA-TMA comprehensive suite of tests support clinicians in optimizing patient management and treatment strategies.

Breakthrough Assays for Improved Patient Outcomes

At Eurofins Viracor, we are committed to revolutionizing diagnostics through our cutting-edge assay innovations. Our tests are meticulously designed to enhance diagnostic accuracy and ultimately improve patient outcomes. By leveraging advanced technologies, we provide comprehensive solutions for a variety of clinical needs, including those related to emerging therapies. Discover how our pioneering assays can support healthcare professionals in delivering the best care possible. Explore our website to learn more about these transformative innovations in diagnostic testing.

ExPeCT anti-CD19 (FMC63) CAR T

NeXGen Fungal / AFB NGS

TTViWATCH - TTV qPCR

NTM Nontuberculous mycobacterial

TA-TMA - Eculizumab • CH50 • sC5b-9

eBook

This interactive eBook presents a synopsis of our operations, services, and, most importantly, our commitment to you and your patients. Viracor delivers accurate results, exceptional turnaround times, and personalized guidance that empowers you to make informed healthcare decisions for your patients.

We are passionate about providing timely, actionable information — never losing sight of the connection between the testing we perform and the patients you serve.

Working Together for Your Patients' Health

Featured News

Chimeric Antigen Receptor T-cell (CAR T) Testing for Pediatric Patients

When it comes to CAR T-cell therapy for pediatric patients, several factors need to be considered during laboratory testing to ensure optimal treatment outcomes. These considerations include the unique biological characteristics of pediatric patients, the specific types of cancers prevalent in this population, and the potential impact of prior treatments. While CAR T-cell therapy offers promising outcomes...

News & Events

The Utility of Hybrid-Capture NGS for Detecting Fungal and Acid-Fast Bacteria in Human Specimens

Next Generation Sequencing (NGS) testing has gained significant importance in the medical clinical laboratory in the United States over the past decade. In recent years, the field of molecular diagnostics has witnessed significant advancements...

Clinical Application of Torque Teno Virus (TTV)

Torque Teno Virus (TTV) is a single-stranded circular DNA virus which has been identified as a surrogate marker of immune competence in transplantation. The monitoring of TTV loads can be a valuable tool in determining the risk of infection or rejection after a person undergoes a transplantation...

TA-TMA Testing: Faster Results and a Comprehensive Approach

Eurofins Viracor's TA-TMA (Transplant-associated thrombotic microangiopathy) testing stands out for its comprehensiveness, offering clinicians a complete assessment of complement pathway regulation and potential deregulation with validated assays for Eculizumab, CH50, and sC5b-9...

Nontuberculous mycobacteria NTM

Nontuberculous mycobacteria (NTM) refer to all the species in the family of mycobacteria that may cause human disease, but do not cause tuberculosis (MTB) or leprosy. In a U.S. study from 2010, it was estimated that approximately 30 people per 100,000 population were infected with these lesser-known species...